COCP

Cocrystal Pharma Inc. Common Stock (COCP)

Stock · NASDAQ · Health Care

$1.02as of 10/16/2026

Price chart

Open in TradingView

Active signals

200 SMA Touch38.6%
High Beta33.6%
Support Reject24.1%
Resistance level
$1.12
Industry
Biotechnology: Pharmaceutical Preparations

COCP Signal Track Record

How signals performed across all stocks →

What COCP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike45-4.3%40%
Bollinger Band Breakout26-9.5%27%
Bollinger Band Breakdown18-7.4%28%
200-Day Moving Average TouchActive now10-4.0%40%
Any 20-session window (baseline)-2.0%43%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About COCP

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV)…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
10

Fundamentals

1-day range
$1.01$1.06
Market cap
$14.20M
P/E (trailing)
—
P/E (forward)
-2.15
EPS (trailing)
$-0.76
Dividend yield
—
Beta
1.64
Avg. volume
57.0K
Dividend pay date
January 24, 2018
52-week range
$0.76$2.03
Next earnings: August 13, 2025 · EPS estimate $-0.32confirmed

How Cocrystal Pharma Inc. Common Stock Makes Money

Where the revenue actually goes — FY2020 annual results

market-wall.comTotalRevenue$2.01MR&D$6.31M (313%)SG&A$5.29M (263%)COCP

Source: 10-K filed Mar 17, 2021 · via SEC EDGAR / Finnhub

Operating Income-$9.59M(-476%)

Forecasts

3 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$10
+880.4%
Median
$8
+684.3%
Low
$6
+488.2%

Cocrystal Pharma Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • COCP
    Cocrystal Pharma Inc. Common Stock
    $1.02
    ▼ 0.97%
    Market cap $14.20MP/E —
    $0.76$2.03
  • KALA
    KALA BIO Inc. Common Stock
    $0.19
    ▼ 1.04%
    Market cap $14.25MP/E —
    $0.2593$95.5
  • AKTX
    Akari Therapeutics plc ADS
    $8.18
    ▼ 7.47%
    Market cap $14.14MP/E Infinity
    $3.02$39.64
  • PTN
    Palatin Technologies Inc. Common Stock
    $6.02
    ▼ 7.24%
    Market cap $14.00MP/E 92.55
    $5.61$31
  • TPST
    Tempest Therapeutics Inc. Common Stock
    $0.624
    ▼ 1.73%
    Market cap $14.42MP/E —
    $0.6801$12.23
  • AEON
    AEON Biopharma Inc. Class A Common Stock
    $0.232
    ▼ 4.53%
    Market cap $13.80MP/E —
    $0.1772$1.45
  • KTTA
    Pasithea Therapeutics Corp. Common Stock
    $0.42
    ▲ 2.44%
    Market cap $14.82MP/E —
    $0.281$2.06

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
320.0K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
752.2K
Total value held
$746.5K
Institutional holders
25
Top holders this quarter
  • Unknown240.0K
  • Unknown123.9K
  • Unknown90.2K
  • Unknown73.7K
  • Unknown51.5K
  • Unknown36.0K
  • Unknown31.9K
  • Unknown20.5K
  • Unknown15.3K
  • Unknown13.1K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.